Small Molecule Drug definition

Small Molecule Drug means any pharmaceutical compound for the treatment of any human or animal disease or condition, the active ingredient of which is a synthetically prepared, or a naturally derived chemical compound [**]; provided, however, that "Small Molecule Drug" specifically excludes any compound which consists of or incorporates as an active ingredient a Protein, a Derivative Protein, a nucleic acid oligomer, or an antibody or any fragment thereof.
Sample 1Sample 2Sample 3
Small Molecule Drug means a small-molecule therapeutic product identified in an assay using a Validated Target, other than a Peptidomimetic Drug, Antisense Drug, Protein Drug, Derivative Protein Drug, Analog Protein Drug, Protein Mimetic Drug, Gene Therapy Drug, Vaccine, or Antibody Drug.
Sample 1
Small Molecule Drug means any therapeutic agent, the active ingredient in which is a Small Molecule, that [**] in a Small Molecule [**]. The term "Small Molecule Drug" shall not include any pharmaceutical product in which the active ingredient is [**].
Sample 1

Examples of Small Molecule Drug in a sentence

  • Robin Ganellin, Stanley Roberts & Roy Jefferis, Introduction to Biological and Small Molecule Drug Research and Development (2013) (reviewed by Dr. Stuart B.

  • Notwithstanding the foregoing, Genentech shall not be prohibited from making a statement regarding the development or commercialization of a Protein Candidate, Licensed Product or Small Molecule Drug and Lexicon shall not be prohibited from making a statement regarding the development or commercialization of a Small Molecule Drug.

  • The areas of research being pursued by the Company include: • Platform Technology - SPORTS Technology; • NDDS based pharmaceutical formulations development; • Development of Vaccines; • Development of biosimilar therapeutic products & monoclonal antibodies; • Small Molecule Drug Discovery (NCE Research) in 3 therapeutic areas, viz.

  • Van Essen, “Enabling Rapid COVID-19 Small Molecule Drug Design Through Scalable Deep Learning of Generative Models,” to appear as Gordon Bell Special Prize finalist in International Journal of High Performance Computing Applications (IJHPCA), 2020.

  • Jefferis (Eds.), Introduction to Biological and Small Molecule Drug Research and Development, Elsevier, Oxford, 2013: pp.

  • Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrom- etry.

  • Mohamed, Nonsteroidal Anti- Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development, Pharmaceuticals, 2010, 3, 1530–1549.

  • The company has successfully introduced the learning management system which will standardise training activities throughout the distribution system.

  • Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders.

  • Together these data emphasize the protective role for RIP1 kinase inhibition in inflammatory disease.2:50 CETSA HT, A Powerful Assay for Small Molecule Drug DiscoveryStina Lundgren, Principal Project Advisor, Pelago BioscienceThe CETSA® HT assay offers a robust label-free method for studying protein− compound interactions in a cellular environment.


More Definitions of Small Molecule Drug

Small Molecule Drug means any therapeutic agent, the active ingredient in which is a Small Molecule, that (a) is identified on the basis of its interaction with a Qualified Target in a Small Molecule screening assay, or (b) is designed or developed using medicinal chemistry, combinatorial chemistry, rational design techniques or other techniques to interact with a Qualified Target. The term "Small Molecule Drug" shall not include any pharmaceutical product in which the active ingredient is (i) a Protein, (ii) any vaccine, (iii) an antibody (whether polyclonal or monoclonal, multiple or single chain, whole or fragment), (iv) a nucleic acid
Sample 1
Small Molecule Drug shall not include any pharmaceutical product in which the active ingredient is (i) a Protein, (ii) any vaccine, (iii) an antibody (whether polyclonal or monoclonal, multiple or single chain, whole or fragment), (iv) a nucleic acid
Sample 1
Small Molecule Drug means a small-molecule therapeutic product, identified in an assay using a Validated Target, other than a Peptidomimetic Drug, Antisense Drug, Protein Drug, Derivative Protein Drug, Analog Protein Drug, Protein Mimetic Drug, Gene Therapy Drug, Vaccine or Antibody Drug. "Stock Purchase, Standstill and Registration Rights Agreement" shall mean the Stock Purchase, Standstill and Registration Rights Agreement by and between ARIAD and HMRI dated as of March 4, 1997.
Sample 1
Small Molecule Drug has the meaning set forth for such term in the Collaboration Agreement between MBI and Eli Xxxlx xxx Company to be executed on or about the Effective Date.
Sample 1
Small Molecule Drug shall not include any pharmaceutical product in which the active ingredient is [**].
Sample 1
Small Molecule Drug means a therapeutic or prophylactic product, the active ingredient of which is a synthetic small molecule (including but not limited to a Peptido Mimetic), a natural product or a macromolecule that (a) is identified in a screening assay on the basis of its interaction with a biological target that has been identified through use of a Program Clone, or (b) is designed or developed using medicinal chemistry, SAR or combinatorial chemistry techniques to interact with a biological target that has been identified through use of a Program Clone, provided, however, that a Small Molecule Drug does not include any Therapeutic Product or any therapeutic and/or prophylactic product in which the active ingredient is a Protein, an Antibody, an Antisense Drug or a Gene Therapy Drug.
Sample 1

Related to Small Molecule Drug

  • Generic Drug means any Prescription Drug approved by the FDA that has the same bio-equivalency as a specific Brand Name Drug.

  • Licensed Compound means [***].

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Phase IV Clinical Trial means a post-registrational Clinical Trial conducted in any country or countries and required as a condition to, or for the maintenance of, any Regulatory Approval for a Product in the Territory.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase II Clinical Trial means a study in humans of the safety, dose ranging and efficacy of a product, which is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial or to file for accelerated approval, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(b) or its foreign equivalents.

  • Active Pharmaceutical Ingredient or “API” means the active pharmaceutical substance of the Drug in bulk form prior to incorporation into the Product.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Manufacturing Know-How means, with respect to the Product or any Variant thereof, the technology, data, designs, processes, methods, specifications and other know-how used in connection with the formulation, manufacture, labeling, packaging, quality control, release testing, and production of the Product, and all ingredients used therein and portions thereof.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Covered drug means any prescription drug that: